Pharma companies' Q1 margins likely to decline despite revenue growth: Goldman Sachs

New Delhi [India], July 9 (ANI): Indian pharmaceutical companies are expected to report improved revenues in the first quarter of FY2026-27, but profitability is likely to come under pressure due to an unfavourable product mix and higher input costs, according to a report by Goldman Sachs. In its Q1FY27 preview, the brokerage said revenues are expected to improve, but margins are likely to decline as companies no